Molecular diagnostics in the management of rhabdomyosarcoma

References

• Pappo AS. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol. 1995;7:361–366.
   PubMedGoogle Scholar
• Abraham J, Nunez-Alvarez Y, Hettmer S, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 2014;28:1578–1591.
   PubMed Web of Science ®Google Scholar
• Hatley ME, Tang W, Garcia MR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012;22:536–546.
   PubMed Web of Science ®Google Scholar
• Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5–10.
   PubMed Web of Science ®Google Scholar
• Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27:1446–1455.
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for intergroup rhabdomyosarcoma study V. J Pediatrhematol Oncol. 2001;23:215–220.
   PubMed Web of Science ®Google Scholar
• Wu HY, Snyder HM 3rd, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when? J Pediatr Urol. 2009;5:501–506.
   PubMed Web of Science ®Google Scholar
• Stevens MC, Rey A, Bouvet N, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology–SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23:2618–2628.
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Gupta AA, Rudzinski ER. What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr. 2014;26:50–56.
   PubMed Web of Science ®Google Scholar
• Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230–235.
   PubMed Web of Science ®Google Scholar
• Davis RJ, D’Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54:2869–2872.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Anderson JR, Hawkins DS, et al. The world health organizationclassification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the children’s oncology group. Arch Pathol Lab Med. 2015;139:1281–1287.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Teot LA, Anderson JR, et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children’s oncology group. Am J Clin Pathol. 2013;140:82–90.
   PubMed Web of Science ®Google Scholar
• Arnold MA, Anderson JR, Gastier-Foster JM, et al. Histology, fusion status, and outcome in alveolar rhabdomyosarcoma with low-risk clinical features: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63:634–639.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatrblood Cancer. 2013;60:1411–1417.
   Google Scholar
• Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28:2151–2158.
   PubMed Web of Science ®Google Scholar
• Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004;64:5539–5545.
   PubMed Web of Science ®Google Scholar
• Duan F, Smith LM, Gustafson DM, et al. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the children’s oncology group. Genes Chromosomes Cancer. 2012;51:662–674.
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012;30:1670–1677.
   PubMed Web of Science ®Google Scholar
• Stegmaier S, Poremba C, Schaefer KL, et al. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS). Pediatr Blood Cancer. 2011;57:406–414.
   PubMed Web of Science ®Google Scholar
• Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol. 2006;24:816–822.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Anderson JR, Lyden ER, et al. Myogenin, AP2beta, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the softtissue sarcoma committee of the children’s oncology group. Am J Surg Pathol. 2014;38:654–659.
   PubMed Web of Science ®Google Scholar
• Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006;66:6936–6946.
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma–genotypic and phenotypic determinants of diagnosis: a report from the Children’s Oncology Group. Am J Pathol. 2009;174:550–564.
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson JR, Buckley JD, et al. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:1240–1246.
   PubMed Web of Science ®Google Scholar
• Wilson RA, Teng L, Bachmeyer KM, et al. A novel algorithm for simplification of complex gene classifiers in cancer. Cancer Res. 2013;73:5625–5632.
   PubMed Web of Science ®Google Scholar
• Hingorani P, Missiaglia E, Shipley J, et al. Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: a report from the Children’s Oncology Group. Clin Cancer Res. 2015;21:4733–4739.
   PubMed Web of Science ®Google Scholar
• Sassoon D, Lyons G, Wright WE, et al. Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature. 1989;341:303–307.
   PubMed Web of Science ®Google Scholar
• Kablar B, Asakura A, Krastel K, et al. MyoD and Myf-5 define the specification of musculature of distinct embryonic origin. Biochem Cell Biol. 1998;76:1079–1091.
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Shukla N, Ameur N, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46:595–600.
   PubMed Web of Science ®Google Scholar
• Van Antwerp ME, Chen DG, Chang C, et al. A point mutation in the MyoD basic domain imparts c-Myc-like properties. Proc Natl Acad Sci U S A. 1992;89:9010–9014.
   PubMed Web of Science ®Google Scholar
• Szuhai K, de Jong D, Leung WY, et al. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol. 2014;232:300–307.
   PubMed Web of Science ®Google Scholar
• Agaram NP, Chen CL, Zhang L, et al. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer. 2014;53:779–787.
   PubMed Web of Science ®Google Scholar
• Lagha M, Kormish JD, Rocancourt D, et al. Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev. 2008;22:1828–1837.
   PubMed Web of Science ®Google Scholar
• Zhao P, Caretti G, Mitchell S, et al. Fgfr4 is required for effective muscle regeneration in vivo. delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem. 2006;281:429–438.
   PubMed Web of Science ®Google Scholar
• Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226–9235.
   PubMed Web of Science ®Google Scholar
• Taylor J, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clininvest. 2009;119:3395–3407.
   PubMed Web of Science ®Google Scholar
• Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4:216–231.
   PubMed Web of Science ®Google Scholar
• Alaggio R, Zhang L, Sung YS, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40:224–235.
   PubMed Web of Science ®Google Scholar
• Sumegi J, Streblow R, Frayer RW, et al. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer. 2010;49:224–236.
   PubMed Web of Science ®Google Scholar
• Olanich ME, Barr FG. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. Expert Opin Ther Targets. 2013;17:607–623.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Tsuchiya K, Otabe O, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 2008;365:568–574.
   PubMed Web of Science ®Google Scholar
• Xia SJ, Holder DD, Pawel BR, et al. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol. 2009;175:2600–2608.
   PubMed Web of Science ®Google Scholar
• Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A. 1996;93:13164–13169.
   PubMed Web of Science ®Google Scholar
• Ebauer M, Wachtel M, Niggli FK, et al. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function ofPAX3/FKHR. Oncogene. 2007;26:7267–7281.
   PubMed Web of Science ®Google Scholar
• Amstutz R, Wachtel M, Troxler H, et al. Phosphorylation regulates transcriptional activity ofPAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res. 2008;68:3767–3776.
   PubMed Web of Science ®Google Scholar
• Loupe JM, Miller PJ, Ruffin DR, et al. Inhibiting phosphorylation of the oncogenic PAX3FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis. 2015;4:e145.
   PubMed Web of Science ®Google Scholar
• Fontaine F, Overman J, Francois M. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell Regen (Lond). 2015;4:2.
   PubMedGoogle Scholar
• Ginsberg JP, Davis RJ, Bennicelli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998;58:3542–3546.
   PubMed Web of Science ®Google Scholar
• Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res. 2010;70:6497–6508.
   PubMed Web of Science ®Google Scholar
• Crose LE, Galindo KA, Kephart JG, et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Invest. 2014;124:285–296.
   PubMed Web of Science ®Google Scholar